Federico Soria1, Esther Morcillo2, Alvaro Serrano3, Alberto Budia4, Inmaculada Fernández5, Tomás Fernández-Aparicio6, Francisco M Sanchez-Margallo2. 1. Endoscopy-Endourology Department, Minimally Invasive Surgery Centre Jesús Usón, Cáceres, Spain. Electronic address: fsoria@ccmijesususon.com. 2. Endoscopy-Endourology Department, Minimally Invasive Surgery Centre Jesús Usón, Cáceres, Spain. 3. Department of Urology, University Hospital Clínico San Carlos, Madrid, Spain. 4. Department of Urology, University Hospital La Fe, Valencia, Spain. 5. Department of Urology, University Hospital de la Princesa, Madrid, Spain. 6. Department of Urology, University Hospital Morales Meseguer, Murcia, Spain.
Abstract
OBJECTIVE: To determine the effects in urinary tract of a new antireflux-biodegradable ureteral stent. MATERIALS AND METHODS: Thirty six ureters belonging to 24 pigs were used. The study began with endoscopic, nephrosonographic, and fluoroscopic assessments. Three study groups of ureters (n = 12) were then specified. In group I, a biodegradable antireflux ureteral stent (BDG-ARS) was inserted in the right ureter of 12 pigs. Group II comprised the left ureter of the same animals, in which a double-pigtail stent was placed for 6 weeks. Group III ureters, belonging to 12 additional animals, were subjected to a ureteropelvic junction obstruction model that was then treated by endopyelotomy and stenting with BDG-ARS. Follow-ups were performed at 3-6 weeks and at 5 months. RESULTS: None of the ureters receiving the BDG-ARS showed any evidence of vesicoureteral reflux (VUR). BDG-ARS degradation took place in a controlled and predictable fashion from the third to the sixth weeks, and no obstructive fragments appeared. No differences were found between groups I and II regarding passive ureteral dilation, but significant differences were found regarding VUR and ureteral orifice damage. BDG-ARS always maintained distal ureteral peristalsis. BDG-ARS in group III showed a 50% positive urine culture rate and a 16.6% migration rate in both BDG-ARS groups. CONCLUSION: BDG-ARS avoided VUR and bladder trigone irritation. In addition, this polymer combination and stent-braided design achieved a consistent biodegradation rate with no obstructive fragments and with uniform degradation between the third and the sixth weeks. Consequently, morbidity associated with ureteral stents might be reduced.
OBJECTIVE: To determine the effects in urinary tract of a new antireflux-biodegradable ureteral stent. MATERIALS AND METHODS: Thirty six ureters belonging to 24 pigs were used. The study began with endoscopic, nephrosonographic, and fluoroscopic assessments. Three study groups of ureters (n = 12) were then specified. In group I, a biodegradable antireflux ureteral stent (BDG-ARS) was inserted in the right ureter of 12 pigs. Group II comprised the left ureter of the same animals, in which a double-pigtail stent was placed for 6 weeks. Group III ureters, belonging to 12 additional animals, were subjected to a ureteropelvic junction obstruction model that was then treated by endopyelotomy and stenting with BDG-ARS. Follow-ups were performed at 3-6 weeks and at 5 months. RESULTS: None of the ureters receiving the BDG-ARS showed any evidence of vesicoureteral reflux (VUR). BDG-ARS degradation took place in a controlled and predictable fashion from the third to the sixth weeks, and no obstructive fragments appeared. No differences were found between groups I and II regarding passive ureteral dilation, but significant differences were found regarding VUR and ureteral orifice damage. BDG-ARS always maintained distal ureteral peristalsis. BDG-ARS in group III showed a 50% positive urine culture rate and a 16.6% migration rate in both BDG-ARS groups. CONCLUSION: BDG-ARS avoided VUR and bladder trigone irritation. In addition, this polymer combination and stent-braided design achieved a consistent biodegradation rate with no obstructive fragments and with uniform degradation between the third and the sixth weeks. Consequently, morbidity associated with ureteral stents might be reduced.
Authors: Julia E de la Cruz; María Soto; Luna Martínez-Plá; Juan Antonio Galán-Llopis; Francisco M Sánchez-Margallo; Federico Soria Journal: Am J Clin Exp Urol Date: 2022-02-15
Authors: Noor Buchholz; Alberto Budia; Julia de la Cruz; Wolfgang Kram; Owen Humphreys; Meital Reches; Raquel Valero Boix; Federico Soria Journal: Polymers (Basel) Date: 2022-04-19 Impact factor: 4.967
Authors: Federico Soria; Julia E de La Cruz; Tomás Fernandez; Alberto Budia; Álvaro Serrano; Francisco M Sanchez-Margallo Journal: Transl Androl Urol Date: 2021-04
Authors: Federico Soria; Julia E de La Cruz; Juan Pablo Caballero-Romeu; Manuel Pamplona; Daniel Pérez-Fentes; Luis Resel-Folskerma; Francisco M Sanchez-Margallo Journal: BMC Urol Date: 2021-02-28 Impact factor: 2.264